603127 昭衍新藥
按盤價 
30.810 -1.170 (-3.659%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 668,575 | -21.28% | 2,018,334 | 2,376,487 | 2,267,971 | 1,516,680 | |
| 減：營業總成本 | 667,394 | -11.38% | 1,763,748 | 1,622,010 | 1,418,766 | 1,086,978 | |
| 其中:營業成本 | 507,935 | -14.12% | 1,444,560 | 1,363,701 | 1,181,660 | 777,558 | |
| 財務費用 | (37,418) | -37.74% | (99,773) | (151,091) | (154,682) | (19,156) | |
| 資產減值損失 | (66,010) | 46.00% | (66,540) | (31,232) | (2,792) | (1,331) | |
| 公允價值變動收益 | 107,019 | -141.61% | (127,049) | (245,642) | 349,567 | 157,777 | |
| 投資收益 | 13,135 | -53.12% | 36,012 | 9,628 | 13,022 | 17,000 | |
| 其中：對聯營企業和合營企業的投資收益 | -- | -- | 15,471 | (3,069) | (2,691) | (426) | |
| 營業利潤 | 79,856 | -145.08% | 104,347 | 507,096 | 1,225,639 | 642,889 | |
| 利潤總額 | 80,120 | -145.18% | 104,039 | 506,950 | 1,240,002 | 642,004 | |
| 減：所得稅費用 | 19,187 | -475.28% | 34,284 | 115,398 | 166,802 | 85,587 | |
| 淨利潤 | 60,932 | -135.38% | 69,755 | 391,553 | 1,073,200 | 556,416 | |
| 減：非控股權益 | -0 | -100.00% | (4,320) | (5,440) | (1,057) | (1,043) | |
| 股東淨利潤 | 60,932 | -135.90% | 74,075 | 396,993 | 1,074,257 | 557,460 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.080 | -134.78% | 0.100 | 0.530 | 1.440 | 1.080 | |
| 每股派息 (元) * | -- | -- | 0.030 | 0.160 | 0.400 | 0.360 | |
| 每股淨資產 (元) * | 10.814 | 2.44% | 10.779 | 11.040 | 15.277 | 18.720 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 28/08/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
